Oral vinorelbine: a narrative review
Evidence & Practice Previous     Next

Oral vinorelbine: a narrative review

Carole Farrell Research fellow, The Christie Hospital NHS Foundation Trust, Manchester, England
Victoria Harmer Macmillan consultant nurse (breast), Imperial College London, England
Mark Foulkes Nurse consultant/lead cancer nurse, Royal Berkshire NHS Foundation Trust, Reading, England
Tom Allum Macmillan patient information and support service manager, Imperial College London, England

The incidence of many cancers is increasing; coupled with a decline in mortality rates (Cancer Research UK 2017a) this translates to more people living with and beyond their cancer diagnosis. Cancer is generally viewed as a chronic condition and this is often true for many diagnosed with metastatic breast cancer (MBC). In advanced/metastatic disease, there is a greater emphasis on promoting patients’ quality of life, and oral treatments can have additional benefits for patients, such as ease of administration, potentially reduced toxicities and fewer hospital visits. Oral vinorelbine was licenced in 2006 for the treatment of non-small cell lung cancer and MBC. This paper provides a narrative review of evidence from clinical trials, outlining the development and clinical application of oral vinorelbine, including implications for clinical practice and patient care.

Correspondence carole.farrell@christie.nhs.uk

Cancer Nursing Practice. 17, 2,25-33. doi: 10.7748/cnp.2018.e1468

Received: 14 July 2017

Accepted: 11 January 2018

Published in print: 08 March 2018

Conflict Of Interest

None declared

Peer review

This article has been subject to external double-blind review and has been checked for plagiarism using automated software